<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02875158</url>
  </required_header>
  <id_info>
    <org_study_id>2015-2212</org_study_id>
    <nct_id>NCT02875158</nct_id>
  </id_info>
  <brief_title>Cyclophotocoagulation in Glaucoma</brief_title>
  <official_title>Modified Settings for Transscleral Cyclophotocoagulation of the Ciliary Body in Glaucoma : A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHU de Quebec-Universite Laval</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CHU de Quebec-Universite Laval</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Transscleral cyclophotocoagulation of the ciliary body is an effective technique to reduce
      intraocular pressure in case of glaucoma. Due to concerns over complications, the main
      indications for this second-line treatment are refractory glaucoma medication / surgery and
      low visual prognosis. The 2000 milliwatts (mW) for 2 seconds settings are used by the
      majority of researchers and clinicians according to the published literature. Some have
      proposed using 1250 mW for 4 seconds to improve the use of this medical procedure.

      The aim of this study is to determine how different parameters affect the efficacy of the
      treatment. This is a prospective double-blinded randomized controlled trial comparing two
      groups, the experimental group using 1250 mW for 4 seconds and the control group using 2000
      mW for 2 seconds.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraocular pressure (IOP) evolution</measure>
    <time_frame>1h, 1 month, 6 months, 12 months, 18 months and 24 months post-op</time_frame>
    <description>The intraocular pressure is measured to determine the efficacy of treatment during follow-up compared to the baseline IOP.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Presence of complications</measure>
    <time_frame>During the intervention, 1 month, 6 months, 12 months, 18 months, 24 months post-op</time_frame>
    <description>Assessment of complications (if applicable).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of medication</measure>
    <time_frame>1 month, 6 months, 12 months, 18 months and 24 months post-op</time_frame>
    <description>Assessment of the topical and oral glaucoma medication at baseline and after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retreatment</measure>
    <time_frame>From the initial treatment up to the last visit (24 months)</time_frame>
    <description>The clinician will assess the need for retreatment based on clinical experience.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>1 month, 6 months, 12 months, 18 months and 24 months post-op</time_frame>
    <description>The visual acuity will be assessed at baseline and each subsequent visit</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Diode laser using conventional settings</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The cyclophotocoagulation protocol is used with the conventional cyclophotocoagulation settings of 2000 mW for 2 seconds.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diode laser using modified settings</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The cyclophotocoagulation protocol is used with the modified cyclophotocoagulation settings of 1250 mW for 4 seconds.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cyclophotocoagulation protocol</intervention_name>
    <description>Intravenous route is installed
Retrobulbar anaesthesia : 50% xylocaine (2%) + 50% bupivicaine
Parameters set for laser treatment (1250mW-4seconds or 2000mW-2 seconds depending on the assigned group)
Pars plana measurement using transillumination (if needed)
Laser treatment applied approximately 1mm post to limbus
Dexamethasone 0,5 mg subconjunctival injection
Post-op regimen: Prednisolone 1% qid x 4 weeks, Atropine 1% bid x 2 weeks + Erythromycin ointment + patch x 6h</description>
    <arm_group_label>Diode laser using conventional settings</arm_group_label>
    <arm_group_label>Diode laser using modified settings</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Conventional cyclophotocoagulation</intervention_name>
    <description>1250 mW for 4 seconds.</description>
    <arm_group_label>Diode laser using conventional settings</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Modified cyclophotocoagulation</intervention_name>
    <description>2000 mW for 2 seconds.</description>
    <arm_group_label>Diode laser using modified settings</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with poorly controlled high pressure glaucoma

          -  Cyclophotocoagulation necessary to prevent visual loss

          -  Cyclophotocoagulation necessary to prevent or to reduce ocular discomfort

        Exclusion Criteria:

          -  Patient has already undergone a cyclophotocoagulation or cryotherapy treatment in the
             same eye for glaucoma

          -  Patients receiving concomitant treatment the same day as the intervention

          -  Patient not able to follow the prescribed post-operative treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Toren, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de recherche du CHU de Québec : Université Laval</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrew Toren, Doctor</last_name>
    <phone>418-682-7511</phone>
    <email>andrewtoren@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre universitaire d'ophtalmologie, Hôpital du Saint-Sacrement. CHU de Québec</name>
      <address>
        <city>Québec</city>
        <zip>G1S 4L8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Toren, Doctor</last_name>
      <phone>418-682-7511</phone>
    </contact>
    <contact_backup>
      <last_name>Jessye Blouin, Adjointe</last_name>
      <phone>418-682-7511</phone>
      <phone_ext>84821</phone_ext>
      <email>cuo.recherche@fmed.ulaval.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Andrew Toren, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2016</study_first_submitted>
  <study_first_submitted_qc>August 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2016</study_first_posted>
  <last_update_submitted>January 24, 2018</last_update_submitted>
  <last_update_submitted_qc>January 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

